ABRDN Physical Gold Shares ETF vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? ABRDN Physical Gold Shares ETF trades at $39.87 (market cap $7.03B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.34 (market cap $2.28B). The key difference: ABRDN Physical Gold Shares ETF is far larger — about 3.1× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| SGOL | SLS | |
|---|---|---|
Market Cap | $7.03B | $2.28B |
Volume | 2,616,502 | 3,128,960 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $51.41 | $15.46 |
52-Week Low | $37.54 | $1.39 |
Typical Hold Time | 57 Days | — |
Enterprise Value | — | $2.15B |
Signals from Pluang's Aura AI — not financial advice
SGOL is currently trading at $39.02, down 1.66% over the past 24 hours amid broader gold market weakness. Technical indicators show a bearish trend with moving averages and oscillators signaling selling pressure. The stock faces headwinds from rising Treasury yields and Federal Reserve rate uncertainty, though some support exists at current price levels. Recent news highlights gold's sensitivity to inflation data and monetary policy expectations.
The outlook for SGOL remains challenged by macroeconomic pressures, with gold prices facing resistance from higher interest rates and dollar strength. However, potential catalysts include geopolitical tensions and any dovish shift in Fed policy. Investors should monitor inflation trends and central bank guidance for directional cues in the gold market.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →